Combination of Benazepril Plus Hydrochlorothiazide in Chinese Patients With Mild to Moderate Essential Hypertension

Last updated: July 6, 2007
Sponsor: Novartis
Overall Status: Completed

Phase

3

Condition

Stress

Williams Syndrome

Vascular Diseases

Treatment

N/A

Clinical Study ID

NCT00367094
CLHT344ACN01
  • Ages > 18
  • All Genders

Study Summary

This study will evaluate efficacy and safety data for benazepril/hydrochlorothiazide in adult Chinese patients with mild to moderate essential hypertension. Patients whose blood pressure is not adequately controlled with benazepril monotherapy during a 4 week run-in period will be randomly allocated to double blind treatment over 8 weeks with either a combination of benazepril/hydrochlorothiazide per day or continuation of benazepril per day.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Male or female patients, age 18 or older

  • Given informed consent

  • Diagnosed as having mild to moderate essential hypertension

Exclusion

Exclusion Criteria:

  • Severe hypertension

  • Significant preexisting cardiovascular and cerebrovascular disease

  • Diabetes mellitus type 1 or poorly controlled diabetes mellitus type II

  • Advanced renal impairment Other protocol-defined inclusion/exclusion criteria may apply.

Study Design

Total Participants: 296
Study Start date:
July 01, 2006
Estimated Completion Date:

Connect with a study center

  • Novartis

    Beijing,
    China

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.